Endothelial lesion in hypertension.

Cor Vasa

Cardiovascular Research Programme, Institute of Clinical and Experimental Medicine, Prague, Czechoslovakia.

Published: June 1989

AI Article Synopsis

  • A study measured circulating endothelial cell counts in hypertensive individuals and healthy controls after a methionine challenge.
  • Hypertensive participants showed a significantly higher endothelial cell count compared to healthy individuals.
  • This method suggests a potential way to indicate latent endothelial lesions in people with hypertension.

Article Abstract

A method for indicating latent endothelial lesion based on circulating endothelial cell count after methionine challenge was used in a group of hypertensives and in healthy controls. A significantly increased cell count was found in hypertensives.

Download full-text PDF

Source

Publication Analysis

Top Keywords

endothelial lesion
8
cell count
8
lesion hypertension
4
hypertension method
4
method indicating
4
indicating latent
4
latent endothelial
4
lesion based
4
based circulating
4
circulating endothelial
4

Similar Publications

An 83-year-old male presented to our Digestive System Department with a 5-day history of severe gastrointestinal (GI) bleeding and a 14-year history of idiopathic thrombocytopenic purpura (ITP) with low platelet levels. Colonoscopy revealed extensive telangiectasias throughout the colon, particularly in the transverse and ascending segments. Standard treatment with proton-pump inhibitors and somatostatin proved ineffective.

View Article and Find Full Text PDF

Introduction: Systemic sclerosis is a complex disease characterized by the fibrosis and vasculopathy.

Aim: We aimed to assess scleroderma by examining involucrin, an early terminal differentiation marker of epidermal keratinocytes.

Material And Methods: Immunolocalization of involucrin was performed in healthy controls and patients with scleroderma lesions by using an immunofluorescence (IF) assay.

View Article and Find Full Text PDF

Rationale: The biodegradable polymer BioMatrix Alpha™ stent contains biolimus A9 drug which is sirolimus derivative increase in lipophicity. The biodegradable polymer sirolimus eluting Combo™ stent is a dual-therapy sirolimus-eluting and CD34+ antobody coated stent capturing endothelial progenitor cells (EPCs).

Hypothesis: The main hypothesis of the SORT OUT XI trial was that the biodegradable polymer biolimus A9 BioMatrix Alpha ™ stent is noninferior to the biodegradable polymer sirolimus eluting Combo™ stent in an all-comers population with coronary artery disease undergoing percutaneous coronary intervention (PCI).

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by widespread immune dysregulation that affects multiple organ systems, including the skin and cardiovascular system. The crosstalk between different cell death pathways-such as apoptosis, necroptosis, and neutrophil extracellular trap (NETosis), plays a pivotal role in the pathogenesis of SLE, influencing both cutaneous and cardiac manifestations. Cutaneous lupus erythematosus (CLE) is one of the most common early signs of SLE, affecting up to 80% of patients.

View Article and Find Full Text PDF

Introduction And Importance: Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare benign vascular tumor characterized by abnormal endothelial proliferation and inflammatory cell infiltration, primarily affecting the head and neck region. The diverse clinical presentations of ALHE pose significant diagnostic challenges, often leading to misdiagnosis. Accurate histopathological examination is crucial for differentiating ALHE from other vascular lesions and guiding appropriate treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!